MS & Immune Disorders

Filter Your Results




New Corticosteroid Approved for Duchenne Muscular Dystrophy

Friday, February 10, 2017—The FDA approved Emflaza (deflazacort) tablets and oral suspension to treat patients age five years and older with Duchenne muscular dystrophy (DMD). Emflaza is the first FDA …

Blood Biomarker for Quick and Accurate Prognosis of MS Identified

Tuesday, February 07, 2017—A newly discovered blood biomarker may aid physicians in identifying the type of multiple sclerosis (MS) in their patients. In a study recently published in Scientific Reports…

Newly Published Phase 3 Data Boost Efficacy Profile of Ocrevus in Primary Progressive and Relapsing MS

Wednesday, January 04, 2017—As the FDA continues its review of the Biologics License Application (BLA) for Genentech’s Ocrevus (ocrelizumab), key phase 3 findings reviewing the agent’s safety…

FDA Extends Review of MS Agent Ocrevus to March 2017

Wednesday, December 21, 2016—The FDA has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the Biologics License Application of Genentech’s investigational agent for the tre…

Cannabinoids and the Endocannabinoid System: Emerging Trends

Shawn Masia, MD and Ryan Zaklin, MD, MA

November/December 2016—Cannabis-derived therapies may offer a great opportunity to modulate the endocannabinoid system, but understanding the risks is paramount.

The Assistance Fund Now Providing Financial Assistance to Patients with Duchenne Muscular Dystrophy

Thursday, October 27, 2016—The Assistance Fund, an independent charitable foundation, is opening a new fund to providing financial assistance for patients living with Duchenne muscular dystrophy. The Du…

Recent Developments

July/August 2016—Once-Monthly Self-Administered Multiple Sclerosis Treatment Zinbryta Wins FDA Approval The FDA has approved Zinbryta (daclizumab, Biogen/AbbVie), a once-monthly, self-…

Amyotrophic Lateral Sclerosis with Atrophy of the Amygdala

Felix Geser, MD, PhD, Leo Hermle, MD, Patrick J. Egan, MD, Johannes Brettschneider, MD, and Tibor C. G. Mitrovics, MD

July/August 2016—Early and pronounced involvement of the amygdala is known to be characteristic for the behavioral variant of frontotemporal dementia, but it may also occur in ALS.


Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.